IRIS PubliCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.525
EU - Europa 1.324
AS - Asia 187
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 3.051
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.515
DE - Germania 445
SE - Svezia 312
IT - Italia 173
CN - Cina 111
IE - Irlanda 97
FR - Francia 85
UA - Ucraina 78
GB - Regno Unito 62
IN - India 34
FI - Finlandia 22
PL - Polonia 16
KR - Corea 11
TR - Turchia 11
BE - Belgio 9
CA - Canada 9
CI - Costa d'Avorio 9
IR - Iran 9
CZ - Repubblica Ceca 6
NL - Olanda 5
ES - Italia 4
SG - Singapore 4
BG - Bulgaria 3
JP - Giappone 3
A2 - ???statistics.table.value.countryCode.A2??? 2
RU - Federazione Russa 2
AR - Argentina 1
CH - Svizzera 1
GR - Grecia 1
HK - Hong Kong 1
HU - Ungheria 1
IL - Israele 1
MA - Marocco 1
MD - Moldavia 1
MX - Messico 1
NG - Nigeria 1
PT - Portogallo 1
SC - Seychelles 1
TW - Taiwan 1
VN - Vietnam 1
Totale 3.051
Salva come PNG Salva come JPEG
Città #
Chandler 423
Ashburn 166
Dublin 94
New York 87
Jacksonville 68
San Mateo 50
Dearborn 45
Ann Arbor 41
Cattolica 39
Milan 35
Princeton 31
Beijing 30
Nürnberg 30
Boston 29
Wilmington 27
Marseille 25
Nanjing 25
Bremen 22
Houston 22
Munich 21
Rome 19
Fairfield 15
Lawrence 14
Warsaw 12
Izmir 11
Lancaster 11
Redwood City 11
Seattle 11
Seoul 11
Leawood 10
Abidjan 9
Brussels 9
Nanchang 9
Shenyang 8
Woodbridge 8
Augusta 7
Cagliari 7
Jiaxing 7
Washington 7
Los Angeles 6
Mountain View 6
Sacramento 6
Andover 5
Brno 5
Norwalk 5
Pune 5
Ardabil 4
Boardman 4
Edinburgh 4
Guasila 4
Hebei 4
San Diego 4
Tianjin 4
Toronto 4
Atlanta 3
Cambridge 3
Changsha 3
Chelsea 3
Costa Mesa 3
Detroit 3
Hefei 3
Helsinki 3
Lappeenranta 3
London 3
Miami 3
Millbury 3
Paris 3
San Jose 3
Shanghai 3
Sofia 3
A Coruña 2
Amsterdam 2
Busto Arsizio 2
Cento 2
Changchun 2
Collegeville 2
Florence 2
Fremont 2
Jinan 2
Kashan 2
Kish 2
Kraków 2
Kunming 2
Lille 2
Monmouth Junction 2
Montreal 2
Mumbai 2
Napoli 2
Pavia 2
Portocannone 2
Raritan 2
Romainville 2
Saint-Fons 2
Singapore 2
Tappahannock 2
Trieste 2
University Park 2
West Palm Beach 2
Wuhan 2
Acton 1
Totale 1.683
Salva come PNG Salva come JPEG
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 147
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 137
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 136
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 131
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 130
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 127
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 113
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 108
Ileal Crohn's disease: CEUS determination of activity 98
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 97
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 92
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 81
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 76
Management of perianal fistulas in Crohn's disease: an up-to-date review 69
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 69
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 66
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 60
Frontiers in drug research and development for inflammatory bowel disease 56
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 56
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 56
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 56
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 53
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 51
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 49
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 49
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 48
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 48
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 46
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 46
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 44
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 43
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 43
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 42
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 42
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 39
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 37
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 37
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 36
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 36
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 35
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 34
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 34
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 33
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 29
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 29
Diet and nutrients in gastrointestinal chronic diseases 29
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 26
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 24
Radiomics could predict surgery at 10 years in Crohn's disease 21
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 21
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 14
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 13
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 8
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 6
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 5
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 5
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 4
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 4
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 4
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 2
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 2
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 2
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 2
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 1
Totale 3.137
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.409
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201945 0 0 0 0 0 0 0 0 0 0 34 11
2019/2020363 54 14 36 13 27 47 27 20 26 10 56 33
2020/2021227 13 17 5 26 27 13 15 10 28 9 54 10
2021/2022409 34 15 8 61 6 10 9 51 7 24 84 100
2022/20231.037 138 139 69 171 64 118 50 95 132 13 32 16
2023/2024559 17 145 27 67 22 117 41 46 40 37 0 0
Totale 3.137